Deputy cost nurse Katie McIntosh administers the primary of two Pfizer/BioNTech COVID-19 vaccine jabs, to Vivien McKay Clinical Nurse Manager on the Western General Hospital, on the primary day of the most important immunisation programme within the British history, in Edinburgh, Scotland Britain December 8, 2020.
Andrew Milligan | Reuters
LONDON — People who have a history of “significant” allergic reactions shouldn’t presently obtain the coronavirus vaccine developed by Pfizer and BioNTech, the U.Ok. drug regulator mentioned on Wednesday.
The U.K’s Medicines and Healthcare merchandise Regulatory Agency up to date its steerage to British well being service trusts on who ought to obtain the vaccine, cautioning that “any person with a history of a significant allergic reaction to a vaccine, medicine or food (such as previous history of anaphylactoid reaction or those who have been advised to carry an adrenaline autoinjector) should not receive the Pfizer BioNtech vaccine.”
The precautionary recommendation got here after two members of Britain’s National Health Service, who obtained the vaccine on Tuesday, skilled allergic reactions to the shot. Both are recovering properly, in response to the nationwide medical director for the NHS.
“As is common with new vaccines, the MHRA have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination,” Professor Stephen Powis, nationwide medical director for the NHS, mentioned in a assertion from NHS England Wednesday.
The U.Ok. was the primary nation on the earth to approve the Pfizer-BioNTech vaccine final week. On Tuesday it started a huge vaccination drive beginning in hospitals, with well being and care dwelling staff and people aged over 80 first in line to be inoculated.
Dr. June Raine, the top of the MHRA, advised a U.Ok. authorities choose committee on Wednesday that the regulator would keep “real-time vigilance” of the vaccine now it it’s being deployed.
“Even last evening we were looking at two case reports of allergic reactions,” she mentioned.
“We know from the extensive clinical trials that this was not a feature, but if we need to strengthen our advice now that we have had this experience in vulnerable populations, the groups selected as a priority, we get that advice to the field immediately.”